Personalised Behavioural Intervention in Cancer Screening Programmes (CANVIA)
20 luglio 2026 aggiornato da: Fundació d'investigació Sanitària de les Illes Balears
Feasibility, Acceptability and Preliminary Efficacy of a Personalised Behavioural Intervention to Improve Adherence to Dietary and Lifestyle Cancer Prevention Recommendations in Adults Attending Breast and Colorectal Cancer Screening Programmes: A Three-Arm Randomised Pilot Trial (CANVIA)
The aim of this clinical trial is to find out whether CANVIA can help adults improve dietary and lifestyle habits related to cancer prevention. CANVIA is a personalised programme based on cancer prevention recommendations from the World Cancer Research Fund and the American Institute for Cancer Research (WCRF/AICR). The programme uses a short questionnaire, called the WCRF/AICR Screener, to give each participant personalised feedback.
This study will include adults aged 50 to 69 years who take part in breast or colorectal cancer screening programmes in Palma, Mallorca, Spain. The study will assess whether participants can complete the CANVIA study procedures and use the programme for six months, whether the CANVIA app and, where applicable, the professional support are acceptable and easy to use, and whether there are early signs that CANVIA may help participants follow cancer prevention recommendations more closely.
Before the pilot trial starts, a small first phase with about 20 to 30 participants will test the study procedures and the mobile app. After this, 132 participants will be assigned by chance to one of three groups. One group will receive only a personalised written report at the start of the study. A second group will use the CANVIA mobile app for six months. A third group will use the CANVIA mobile app and also receive support from health professionals for six months.
Participants will complete study assessments at the start of the study, after three months and after six months. Participants in the app groups will receive personalised messages, educational resources and weekly goals or challenges. Some participants from the app groups will also be invited to take part in focus groups at the end of the study to share their experiences and suggestions.
Panoramica dello studio
Stato
Stato
Non ancora reclutamento
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
CANVIA is a personalised behavioural intervention designed to support adherence to dietary and lifestyle recommendations for cancer prevention. The intervention is based on the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Cancer Prevention Recommendations and uses the WCRF/AICR Screener to assess individual adherence, generate personalised feedback, and tailor intervention intensity and content.
This study corresponds to the prospective feasibility evaluation of CANVIA. It will be conducted within population-based breast and colorectal cancer screening programmes in Palma, Mallorca, Spain, among adults aged 50 to 69 years. The purpose of the study is to evaluate whether CANVIA is feasible, usable, acceptable and engaging in this public health setting, and to explore its preliminary efficacy for improving adherence to WCRF/AICR cancer prevention recommendations.
The study will be conducted in two sequential quantitative phases, followed by an embedded qualitative component. First, a single-arm proof-of-concept phase will include approximately 20 to 30 participants. This phase will assess the operational readiness of the recruitment pathway, study procedures, data collection system, mobile application and intervention delivery. Findings from this phase will be used to refine study procedures and digital tools before initiating the randomised pilot feasibility trial.
The subsequent pilot trial will use a three-arm, parallel-group, randomised design with an anticipated enrolment of 132 participants. Participants will be randomly assigned in a 1:1:1 ratio to one of three groups: a control group receiving a personalised baseline feedback report, a mobile app-based CANVIA intervention, or the same mobile app-based intervention combined with structured support from health professionals.
In the active intervention groups, the WCRF/AICR Screener score will be used to classify participants according to their need for lifestyle change and to tailor the intensity and target behaviours of the intervention. The mobile app-based intervention will include tailored messages, educational resources and app-based goals or challenges. Participants receiving additional professional support will also have structured contacts focused on reviewing personalised recommendations, supporting goal setting, monitoring progress, providing feedback and addressing barriers to change.
The intervention will last six months and will be organised into two three-month blocks. The WCRF/AICR Screener will be repeated at Month 3 to monitor changes in adherence and, where appropriate, to update intervention intensity and target behaviours for the second intervention block. Study assessments will be conducted at baseline, Month 3 and Month 6.
The planned pilot trial sample size is 132 participants, with 44 participants per arm. This sample size allows for up to 30% loss to follow-up and is intended to support the assessment of feasibility outcomes and exploratory between-group comparisons in WCRF/AICR Screener score at Month 6.
Main evaluation domains will include feasibility, usability, acceptability, app engagement and preliminary efficacy. Analyses of the pilot trial will follow the intention-to-treat principle. Preliminary efficacy in improving adherence to cancer prevention recommendations will be explored using a linear mixed model including study arm, time, and the arm-by-time interaction; planned pairwise comparisons at Month 6 will be reported with 95% confidence intervals.
Focus groups conducted at Month 6 with participants from the intervention groups will explore participant experiences, barriers and facilitators to engagement, and suggestions for improving the intervention and study procedures before future larger-scale evaluation. Qualitative data from focus groups will be analysed thematically.
Tipo di studio
Tipo di studio
Interventistico
Iscrizione (Stimato)
Iscrizione
162
Fase
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
Contatto studio
- Nome: Dora Romaguera Bosch, PhD
- Numero di telefono: 64517 +34871205000
- Email: mariaadoracion.romaguera@idisba.es
Backup dei contatti dello studio
- Nome: León González Casas, Máster
- Numero di telefono: +34673829884
- Email: octavioleon.gonzalez@idisba.es
Luoghi di studio
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, Spagna, 07120
- Fundació Institut d'Investigació Sanitària Illes Balears
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Sì
Descrizione
Inclusion Criteria:
- Women and men participating in the breast and/or colorectal cancer screening programmes within the Sector Sanitari Ponent, Hospital Universitari Son Espases.
- Aged 50 to 69 years.
- No history of cancer.
- No evidence of an active tumour process, defined as a negative screening result and/or negative complementary tests, as applicable.
- Able and willing to provide written informed consent prior to any study procedure.
- Sufficient verbal and reading comprehension of Spanish and/or Catalan to complete study procedures and questionnaires.
- Access to a smartphone with internet connection and sufficient storage, and ability to install and use the study application.
- Availability to attend the IdISBa Clinical Trials Unit at Hospital Universitari Son Espases for scheduled in-person visits, as agreed with the research team.
Exclusion Criteria:
- Any diagnosed condition that severely affects dietary intake or requires medically prescribed restrictive nutrition, such as an eating disorder, severe renal or gastrointestinal disease, or parenteral nutrition.
- Any diagnosed condition that severely limits the ability to perform light or moderate physical activity.
- Excessive alcohol consumption, defined as more than 6 standard units per day, or problematic substance use.
- Concurrent participation in another clinical trial that, in the investigator's judgement, may interfere with the present study outcomes.
- Body mass index <18.5 kg/m² or >40 kg/m²
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
3
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Control group
Participants allocated to the control group will complete the scheduled study assessments through the study data-collection system and will receive the personalised baseline feedback report based on their WCRF/AICR Screener responses.
They will not have access to the active intervention module of the mobile application and will not receive tailored messages, weekly challenges, or structured health professional support during the 6-month intervention period.
Participants in the control group will be offered post-trial access to the intervention if it is shown to be beneficial and where feasible.
|
The personalised baseline feedback report consists of an individualised report provided at baseline, based on each participant's WCRF/AICR Screener responses.
The report provides feedback on adherence to cancer prevention recommendations.
In the control group, it is delivered as paper-based personalised recommendations and is the only active behavioural component delivered during the 6-month intervention period.
In the active intervention arms, the corresponding baseline feedback is delivered through the mobile application.
|
|
Sperimentale: Intervention A: mobile app intervention
Participants allocated to Intervention A will receive the personalised baseline feedback report and access to the active intervention module of the mobile application.
This module will include tailored messages, educational resources, infographics, recipes, physical-activity resources, alcohol-related resources, general cancer-prevention information, and a weekly goal/challenge component.
The intervention will be delivered over a 6-month period, with reassessment of the WCRF/AICR Screener at Month 3 to update tailoring where appropriate.
|
The personalised baseline feedback report consists of an individualised report provided at baseline, based on each participant's WCRF/AICR Screener responses.
The report provides feedback on adherence to cancer prevention recommendations.
In the control group, it is delivered as paper-based personalised recommendations and is the only active behavioural component delivered during the 6-month intervention period.
In the active intervention arms, the corresponding baseline feedback is delivered through the mobile application.
The CANVIA mobile app intervention consists of access to the active intervention module of the mobile application.
The module includes tailored messages, educational resources, infographics, recipes, physical-activity resources, alcohol-related resources, general cancer-prevention information, and a weekly goal/challenge component.
Delivery is organised over a 6-month period.
Intervention intensity and target behaviours are tailored according to the WCRF/AICR Screener-based category and may be updated after the Month 3 reassessment.
|
|
Sperimentale: Intervention B: mobile app intervention plus professional support
Participants allocated to Intervention B will receive all components of Intervention A, combined with structured support from health professionals.
Health professionals involved in Intervention B will receive training and a delivery guide covering intervention aims, Screener-based tailoring procedures, core behaviour-change conversation skills, and documentation of professional contacts.
The intervention and professional support contacts will be delivered over a 6-month period, with reassessment of the WCRF/AICR Screener at Month 3. Contacts will focus on reviewing personalised recommendations, supporting goal setting, monitoring progress, providing tailored feedback, identifying barriers and facilitators, reinforcing implemented changes, and adapting strategies where needed.
|
The personalised baseline feedback report consists of an individualised report provided at baseline, based on each participant's WCRF/AICR Screener responses.
The report provides feedback on adherence to cancer prevention recommendations.
In the control group, it is delivered as paper-based personalised recommendations and is the only active behavioural component delivered during the 6-month intervention period.
In the active intervention arms, the corresponding baseline feedback is delivered through the mobile application.
The CANVIA mobile app intervention consists of access to the active intervention module of the mobile application.
The module includes tailored messages, educational resources, infographics, recipes, physical-activity resources, alcohol-related resources, general cancer-prevention information, and a weekly goal/challenge component.
Delivery is organised over a 6-month period.
Intervention intensity and target behaviours are tailored according to the WCRF/AICR Screener-based category and may be updated after the Month 3 reassessment.
Additional health professional support consists of structured contacts delivered in addition to the CANVIA mobile app intervention.
Health professionals will receive training and a delivery guide to support standardised delivery and intervention fidelity.
Support is tailored according to the WCRF/AICR Screener-based category and may be updated after the Month 3 reassessment.
Contacts focus on reviewing personalised recommendations, supporting goal setting, monitoring progress, providing tailored feedback, identifying barriers and facilitators, reinforcing implemented changes, and adapting strategies where needed.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of invited individuals enrolled and randomised
Lasso di tempo: From invitation to baseline randomisation in the randomised pilot trial
|
Recruitment feasibility in the randomised pilot trial will be assessed as the number of invited individuals who are enrolled and randomised divided by the total number of invited individuals.
Reasons for non-participation and ineligibility will be recorded when available.
|
From invitation to baseline randomisation in the randomised pilot trial
|
|
Proportion of randomised participants retained at Month 3 and Month 6
Lasso di tempo: Month 3 and Month 6
|
Retention will be assessed as the number of randomised participants who complete follow-up assessments at Month 3 and Month 6 divided by the total number of randomised participants.
Reasons for withdrawal or loss to follow-up will be summarised when available.
|
Month 3 and Month 6
|
|
Proportion of expected outcome and covariate data completed
Lasso di tempo: Baseline, Month 3 and Month 6
|
Data completeness will be assessed as the number of completed expected outcome and covariate data fields divided by the total number of expected outcome and covariate data fields at each scheduled assessment time point.
This will include completion of the WCRF/AICR Screener and the study questionnaire battery
|
Baseline, Month 3 and Month 6
|
|
Proportion of scheduled study visits attended
Lasso di tempo: Baseline, Month 3 and Month 6
|
Attendance at study visits will be assessed as the number of scheduled data-collection visits attended divided by the total number of scheduled data-collection visits.
This measure will be assessed across all study arms.
|
Baseline, Month 3 and Month 6
|
|
Proportion of planned health professional support contacts attended
Lasso di tempo: From baseline to Month 6
|
Attendance at professional support contacts will be assessed in Intervention B as the number of planned health professional support contacts attended divided by the total number of planned health professional support contacts.
Contacts may be planned according to the participant's WCRF/AICR Screener-based category.
|
From baseline to Month 6
|
|
Number of technical incidents requiring study staff support
Lasso di tempo: From baseline to Month 6
|
Operational and technical feasibility will be assessed as the number of technical incidents requiring support from study staff during the intervention period.
Technical incidents may include problems related to access to digital study tools, use of the CANVIA mobile application, completion of digital assessments, or other technical issues affecting intervention delivery or data collection.
|
From baseline to Month 6
|
|
Mean overall score on the mHealth App Usability Questionnaire at Month 6
Lasso di tempo: Month 6
|
App usability will be assessed in the app-based intervention arms using the Spanish culturally adapted version of the mHealth App Usability Questionnaire, standalone patient version.
Items are rated on a 7-point Likert scale, with higher scores indicating better perceived usability.
The outcome will be summarised as the mean overall usability score at Month 6.
|
Month 6
|
|
Mean item scores on the adapted Research Participant Perception Survey-Long Form at Month 6
Lasso di tempo: Month 6
|
Acceptability and participant perception will be assessed using an adapted Spanish version of the Research Participant Perception Survey-Long Form.
Responses will be summarised as mean item scores for pre-specified items assessing participants' perception of the intervention and study procedures.
Higher or more favourable scores will indicate better perceived acceptability and participant experience.
|
Month 6
|
|
Number of CANVIA mobile app logins or sessions per participant through Month 6
Lasso di tempo: From baseline to Month 6
|
App engagement will be assessed in the app-based intervention arms using automatically captured usage data.
This outcome will be summarised as the number of CANVIA mobile app logins or sessions per participant during the 6-month intervention period.
|
From baseline to Month 6
|
|
Number of active days in the CANVIA mobile app per participant through Month 6
Lasso di tempo: From baseline to Month 6
|
App engagement will be assessed in the app-based intervention arms using automatically captured usage data.
This outcome will be summarised as the number of days on which each participant actively used the CANVIA mobile app during the 6-month intervention period.
|
From baseline to Month 6
|
|
Proportion of expected key in-app actions completed through Month 6
Lasso di tempo: From baseline to Month 6
|
App engagement will be assessed in the app-based intervention arms using automatically captured usage data.
This outcome will be calculated as the number of completed key in-app actions divided by the number of expected or pre-specified key in-app actions during the 6-month intervention period.
Key in-app actions may include opening tailored content, accessing resources, responding to weekly challenges, or completing other pre-specified intervention-related actions.
|
From baseline to Month 6
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean change in WCRF/AICR Screener score from baseline to Month 6
Lasso di tempo: Baseline and Month 6
|
Preliminary efficacy will be assessed as the mean change in adherence to cancer prevention recommendations, measured using the WCRF/AICR Screener score.
The total score ranges from 0 to 7 in this study, with higher scores indicating greater adherence to the WCRF/AICR Cancer Prevention Recommendations.
|
Baseline and Month 6
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Themes describing participant experiences from Month 6 focus groups
Lasso di tempo: Month 6
|
Participant experiences will be explored through focus groups with participants from the intervention arms.
Focus groups will examine perceived acceptability and appropriateness of the intervention, barriers and facilitators to engagement and participation, and suggestions for improving the intervention and study procedures.
Data will be analysed thematically.
|
Month 6
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Dora Romaguera Bosch, PhD, CIBER (Consorcio de Investigación Biomédica en Red); IdISBa (Fundació Institut d'Investigació Sanitària Illes Balears)
- Investigatore principale: Guillem Artigues Vives, PhD, Conselleria de Salut, Govern de les Illes Balears
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Pubblicazioni generali
- Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB.
- Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021 Sep 30;374:n2061. doi: 10.1136/bmj.n2061.
- Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. doi: 10.1186/1748-5908-4-50.
- Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016 Oct 24;355:i5239. doi: 10.1136/bmj.i5239.
- Czajkowski SM, Powell LH, Adler N, Naar-King S, Reynolds KD, Hunter CM, Laraia B, Olster DH, Perna FM, Peterson JC, Epel E, Boyington JE, Charlson ME. From ideas to efficacy: The ORBIT model for developing behavioral treatments for chronic diseases. Health Psychol. 2015 Oct;34(10):971-82. doi: 10.1037/hea0000161. Epub 2015 Feb 2.
- Lucas-Carrasco R. The WHO quality of life (WHOQOL) questionnaire: Spanish development and validation studies. Qual Life Res. 2012 Feb;21(1):161-5. doi: 10.1007/s11136-011-9926-3. Epub 2011 May 25.
- Rodriguez-Munoz S, Corella C, Abarca-Sos A, Zaragoza J. Validation of three short physical activity questionnaires with accelerometers among university students in Spain. J Sports Med Phys Fitness. 2017 Dec;57(12):1660-1668. doi: 10.23736/S0022-4707.17.06665-8. Epub 2017 Mar 1.
- Zhou L, Bao J, Setiawan IMA, Saptono A, Parmanto B. The mHealth App Usability Questionnaire (MAUQ): Development and Validation Study. JMIR Mhealth Uhealth. 2019 Apr 11;7(4):e11500. doi: 10.2196/11500.
- Shams-White MM, Brockton NT, Mitrou P, Romaguera D, Brown S, Bender A, Kahle LL, Reedy J. Operationalizing the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Cancer Prevention Recommendations: A Standardized Scoring System. Nutrients. 2019 Jul 12;11(7):1572. doi: 10.3390/nu11071572.
- Avery KN, Williamson PR, Gamble C, O'Connell Francischetto E, Metcalfe C, Davidson P, Williams H, Blazeby JM; members of the Internal Pilot Trials Workshop supported by the Hubs for Trials Methodology Research. Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies. BMJ Open. 2017 Feb 17;7(2):e013537. doi: 10.1136/bmjopen-2016-013537.
- Schwarzer R, Baessler J. Evaluación de la autoeficacia: adaptación española de la Escala de Autoeficacia General. Ansiedad y Estrés. 1996;2(1):1-8.
- Schwarzer R, Jerusalem M. Generalized Self-Efficacy Scale. In: Weinman J, Wright S, Johnston M, editors. Measures in Health Psychology: A User's Portfolio. Causal and Control Beliefs. Windsor: NFER-NELSON; 1995. p. 35-37.
- American Institute for Cancer Research, World Cancer Research Fund. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. A Summary of the Third Expert Report. 2018.
- Solans M, Chan DSM, Mitrou P, Norat T, Romaguera D. A systematic review and meta-analysis of the 2007 WCRF/AICR score in relation to cancer-related health outcomes. Ann Oncol. 2020 Mar;31(3):352-368. doi: 10.1016/j.annonc.2020.01.001. Epub 2020 Jan 8.
- Mellor K, Eddy S, Peckham N, Bond CM, Campbell MJ, Lancaster GA, Thabane L, Eldridge SM, Dutton SJ, Hopewell S. Progression from external pilot to definitive randomised controlled trial: a methodological review of progression criteria reporting. BMJ Open. 2021 Jun 28;11(6):e048178. doi: 10.1136/bmjopen-2020-048178.
- de la Fuente-Arrillaga C, Ruiz ZV, Bes-Rastrollo M, Sampson L, Martinez-Gonzalez MA. Reproducibility of an FFQ validated in Spain. Public Health Nutr. 2010 Sep;13(9):1364-72. doi: 10.1017/S1368980009993065. Epub 2010 Jan 28.
- Kost RG, de Rosa JC. Impact of survey length and compensation on validity, reliability, and sample characteristics for Ultrashort-, Short-, and Long-Research Participant Perception Surveys. J Clin Transl Sci. 2018 Feb;2(1):31-37. doi: 10.1017/cts.2018.18. Epub 2018 Jul 6.
- Chaplin A, Nafria M, Prohens L, Morey M, Rayo E, Shams-White MM, Brockton N, Reedy J, Mitrou P, Castello A, Toledo E, Fito M, Castaner O, Zomeno MD, Eguaras S, Sese A, Romaguera D. Development and validation of a short screener to evaluate adherence to the World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations. Clin Nutr. 2025 Apr;47:275-281. doi: 10.1016/j.clnu.2025.02.033. Epub 2025 Mar 3.
- Konieczna J, Chaplin A, Paz-Graniel I, Croker H, Becerra-Tomas N, Markozannes G, Tsilidis KK, Dossus L, Gonzalez-Gil EM, Park Y, Krebs J, Weijenberg MP, Baskin ML, Copson E, Lewis SJ, Seidell JC, Chowdhury R, Hill L, Chan DS, Romaguera D. Adulthood dietary and lifestyle patterns and risk of breast cancer: Global Cancer Update Programme (CUP Global) systematic literature review. Am J Clin Nutr. 2025 Jan;121(1):14-31. doi: 10.1016/j.ajcnut.2024.10.003. Epub 2024 Oct 23.
- Chu AH, Lin K, Croker H, Kefyalew S, Markozannes G, Tsilidis KK, Park Y, Krebs J, Weijenberg MP, Baskin ML, Copson E, Lewis SJ, Seidell JC, Chowdhury R, Hill L, Chan DS, Lee DH, Giovannucci EL. Dietary-Lifestyle Patterns and Colorectal Cancer Risk: Global Cancer Update Programme (CUP Global) Systematic Literature Review. Am J Clin Nutr. 2025 May;121(5):986-998. doi: 10.1016/j.ajcnut.2025.01.014. Epub 2025 Jan 11.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Stimato)
Inizio studio
1 ottobre 2026
Completamento primario (Stimato)
Completamento primario
1 maggio 2028
Completamento dello studio (Stimato)
Completamento dello studio
1 maggio 2028
Date di iscrizione allo studio
Primo inviato
Primo inviato
20 luglio 2026
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
20 luglio 2026
Primo Inserito (Effettivo)
Primo Inserito
23 luglio 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
23 luglio 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
20 luglio 2026
Ultimo verificato
Ultimo verificato
1 luglio 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- PI24/01647
- IB 6026/26 PI (Altro identificatore: Medicinal Products Research Ethics Committee of the Balearic Islands (CEIm-IB))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
Individual participant data will not be made available to other researchers.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .